News & Updates

In the treatment of patients with chronic obstructive pulmonary disease (COPD), the investigational dual phosphodiesterase (PDE) 3 and 4 inhibitor TQC3721 helps improve lung function, according to a phase 2 PACER-II study.

In the treatment of patients with resected non–small cell lung cancer (NSCLC) without sensitizing EGFR and ALK alterations, adjuvant nivolumab does not appear to yield improvements in disease-free survival (DFS) when given after planned adjuvant chemotherapy and/or radiotherapy, according to a phase 3 study.

Among patients hospitalized with severe SARS-CoV-2 infection, acute-phase systemic corticosteroid exposure is associated with greater odds of long COVID symptoms, according to a study.

A higher arousal threshold is associated with a more severe hypoxic burden in patients with obstructive sleep apnea (OSA) but shows a nonlinear correlation with apnea-hypopnea index (AHI), reveals a study.

New drug applications approved by US FDA as of 1-15 May 2026 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

High-dose inactivated influenza vaccine (HD-IIV) confers improved protection against hospitalization outcomes for older adults when compared with standard-dose inactivated influenza vaccine (SD-IIV), according to the results of a meta-analysis.

In the first-line treatment of patients with advanced squamous non-small cell lung cancer (NSCLC) in China, the combination of ivonescimab plus chemotherapy significantly improves overall survival (OS) compared with tislelizumab plus chemotherapy, according to the phase III HARMONi-6 trial.